Delta infection and drug abuse in Merseyside

Area of Science:

• Hepatology
• Virology
• Infectious Diseases

Background:

• Delta agent (HDV) is a small RNA virus requiring hepatitis B virus (HBV) for replication.
• HDV infection is primarily observed in intravenous drug users (IDUs) and their contacts in Northern Europe, North America, and Britain.
• HDV infection can lead to chronic active hepatitis, posing a significant health concern.

Purpose of the Study:

• To investigate the prevalence of delta virus infection among drug abusers in Merseyside.
• To assess the trends of delta virus infection in hepatitis B surface antigen (HBsAg) carriers with a history of drug abuse.
• To highlight the importance of monitoring delta virus infection in at-risk populations.

Main Methods:

• Analysis of blood samples from acute hepatitis B cases and HBsAg carriers in Merseyside between 1982 and 1987.
• Testing for delta virus infection using delta antibody detection.
• Comparing prevalence rates between drug abusers and non-drug abusers.

Main Results:

• Delta virus infection was found in 4.4% of acute hepatitis B cases among drug abusers.
• The proportion of HBsAg carriers with a history of drug abuse testing positive for delta antibody increased from 10% in 1984 to 30.8% in 1987.
• Delta antibody was detected in 32.4% of HBsAg carriers with a history of drug abuse, compared to only 1.6% in those without admitted drug abuse.

Conclusions:

• Delta virus infection represents a significant public health problem among drug abusers in Britain.
• Control strategies should focus on curbing drug abuse and utilizing hepatitis B vaccination.
• Prioritizing delta antibody testing in HBsAg carriers with a history of drug abuse is essential for surveillance.